ChronicleBio

We’ve launched! #ChronicleBio is building an AI-ready data platform for neuroimmune disorders like #POTS, #MECFS, #LongCOVID & more. These conditions affect 250M+ people but remain under-researched. We’re here to change that. 🔗 chroniclebio.com/news/merging-d… #Biotech #HealthAI

🧵: It is surreal to be sitting in a room watching scientists passionately debate pathways, biomarkers, immune signatures, and research design for illnesses that completely changed my own life.

#WhyWeChronicle: Dr. John Mumm, Chief Scientific Officer Dr. Mumm is a three-decade immunology innovator who has founded multiple companies and authored more than 30 peer-reviewed publications. He brings transformational drug-development expertise to ChronicleBio.

#ChronicleBio has appointed immuno-oncology pioneer John Mumm, Ph.D., as CSO, joining computational biology leader Yambazi Banda, Ph.D., to translate multi-omic biological signal into targeted therapeutics for complex chronic conditions. Announcement: prnewswire.com/news-releases/…

If there is one good thing that can come out of having my health issues exposed to the world, it’s raising awareness for complex chronic conditions like POTS, MECFS, Long Covid or EDS. 🧵 businessinsider.com/what-is-pots-f…

So, to our courageous co-founder, and all patients who have lost pieces of their identities to chronic illness: We know why we are here. We know what is at stake. We are determined. With love from the lab, The ChronicleBio Team

In just our first year, hundreds of participants have enrolled in the Chronicle I Study through our clinic partners around the world. Our scientists are already generating early signals across complex chronic conditions and have identified multiple potential drug targets.

We exist to change outcomes like this. ChronicleBio Co-founder Fidji Simo recently announced she is taking medical leave from OpenAI due to Postural Orthostatic Tachycardia Syndrome (POTS).

The heart of what we do from one of the visionaries behind it. In this conversation from the #CNBCCures Summit, #ChronicleBio Co-founder @fidjissimo shares how biological data & advanced AI models can accelerate discovery for poorly understood diseases. cnbc.com/video/2026/03/…

#WhyWeChronicle: Dr. Cortney Gensemer, Principal Translational Scientist Dr. Gensemer joined ChronicleBio from MUSC’s Norris Lab, where her pioneering work spanned molecular biology and genetic research with a focus on Ehlers Danlos Syndrome.

We are so grateful for your participation and appreciate you joining us on this vital journey. Thank you to our clinic partners and participants who make this study possible!

If you choose to join the Chronicle I Study and contribute health data and biospecimens, you’ll be part of the effort to build one of the most advanced datasets on your condition, turning lived experience into breakthroughs. Sign Up: mydatahelps.org/identityserver…

The Chronicle I Study is just the beginning. About the study: